Erasca logo
Erasca
ERAS | NASDAQ
Chart Builder DCF Calculator
$15.11
-$0.55 (-3.51%)
At close: Nov 16, 2026, 4:00 PM ET
$15.11
$0.00 (0.00%)
After-hours: Nov 16, 2026, 7:30 PM ET

Erasca Company Profile

Company profile explained

Company Profile

Erasca, Inc. is a biopharmaceutical company in the clinical development stage, primarily focused on identifying, advancing, and commercializing therapeutic solutions for malignancies propelled by the RAS/MAPK pathway. The firm's pipeline features several key experimental drugs: ERAS-007, an orally administered ERK1/2 inhibitor designed to address non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor targeting patients with advanced or metastatic solid tumors. Additionally, Erasca is progressing ERAS-801, an EGFR inhibitor capable of penetrating the central nervous system, intended for recurrent glioblastoma multiforme. The company was founded in 2018 and maintains its headquarters in San Diego, California.

Key Executives

Name Position
Jonathan E. Lim Co-Founder, Chairman & Chief Executive Officer
David Chacko Chief Financial Officer & Chief Business Officer
Ebun S. Garner Chief Legal Officer & Corporate Secretary
Lisa Tesvich-Bonora Chief People Officer
Nik Chetwyn Chief Operating Officer
Alison Tjosvold Milhous Senior Vice President of Accounting
Brian L. Baker Senior Vice President of Finance
Chandra D. Lovejoy Chief Regulatory Affairs Officer
Michael D. Varney Chairman of Research & Development, Scientific Advisory Board Member and Director
Robert Shoemaker Chief Scientific Officer
Shannon Morris Chief Medical Officer

Latest SEC Filings

Date Type Title
Oct 16, 2026 8-K Current Report
Aug 24, 2026 8-K Current Report
Aug 14, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Aug 12, 2026 4 Filing
Aug 12, 2026 3 Filing
Aug 11, 2026 S-8 Filing
Aug 11, 2026 10-Q Quarterly Report
Aug 11, 2026 8-K Current Report
Aug 10, 2026 8-K Current Report
Jul 14, 2026 8-K Current Report
View All SEC Filings ➞
Erasca
Erasca logo
Country United States
IPO Date Jul 16, 2021
Industry Biotechnology
Sector Healthcare
Employees 103
CEO Jonathan E. Lim

Contact Details

3115 Merryfield Row San Diego, California 92121 United States

Stock Details

Ticker Symbol ERAS
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001761918
CUSIP Number 29479A108
ISIN Number US29479A1088
SIC Code 2834

Recent News

More News ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.